On October 18, 2023, Y-mAbs Therapeutics, Inc. announced that the Board of Directors of the Company has appointed Michael Rossi to serve as the Company?s President and Chief Executive Officer, increased the size of the Board from seven to eight directors, in each case effective as of the date of the commencement of his employment with the Company, which is expected to be November 6, 2023 (the ?Effective Date?). On the Effective Date, Mr. Rossi will replace Thomas Gad in the role of Chief Executive Officer of the Company. Mr. Gad, the Company?s Founder, who has been serving as interim Chief Executive Officer, President and Head of Business Development & Strategy, will cease to serve in those roles as of the Effective Date and will assume the roles of Chief Business Officer of the Company and Vice Chairman of the Board.

Mr. Rossi, age 52, has more than 30 years of experience in the radiopharmaceutical industry, most recently as the Medical Group President of Mirion Technologies, Inc., which he joined in October 2022. Prior to that, Mr. Rossi was employed by Advanced Accelerator Applications, from June 2019 until June 2022, most recently as the Head of Radioligand Imaging. Before that, Mr. Rossi was at Jubilant DraxImage Radiopharma, from April 2014 until May 2019, most recently as the President of the Jubilant Radiopharmaceuticals business.

Mr. Rossi?s past experience also includes positions with GE Healthcare, Tyco Healthcare/Mallinckrodt and Synco International Corp. Mr. Rossi currently sits on the boards of directors of the private companies Archeus Technologies Ltd. and Nucleus Radiopharma. Mr. Rossi earned a B.S. in Pharmacy from the University of the Sciences, Philadelphia College of Pharmacy and holds an Authorized Nuclear Pharmacist Certification from Butler University.

He remains a Licensed Pharmacist in the state of Pennsylvania.